Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-mcfzb Total loading time: 0 Render date: 2025-03-07T03:29:13.285Z Has data issue: false hasContentIssue false

7 - Contemporary Issues in the Systemic Treatment of Lung Cancer

Published online by Cambridge University Press:  12 August 2009

By
Alistair Ring  and
Joseph Prendiville
Edited by
Sujal R. Desai
Alistair Ring
Affiliation:
Guy's, King's and St Thomas' Cancer Centre, London, UK
Joseph Prendiville
Affiliation:
Guy's, King's and St Thomas' Cancer Centre, London, UK
Sujal R. Desai
Affiliation:
King's College Hospital, London
Get access

Summary

Introduction

Lung cancer is conveniently divided into two major histopathological subtypes known as small cell lung cancer (SCLC) and non-small cell lung cancer, (NSCLC) by virtue of their very differing responses to chemotherapy. Since the introduction of systemic chemotherapy in the 1970s SCLC has been regarded as a highly chemosensitive tumour where chemotherapy can dramatically alter the natural course of the disease. In contrast NSCLC has been regarded as relatively resistant to cytotoxic chemotherapy. While most patients with SCLC continue to derive significant benefit from chemotherapy which always warrants its use, there has not been dramatic progress in further improving survival. This is in spite of much innovative research over the past two decades. In contrast over the same period of time, we have witnessed developments in the treatment of advanced-stage NSCLC where we have gone from a situation of uncertainty as to whether even first line chemotherapy was of any value at all, to now knowing that patients with advanced-stage disease gain survival advantage and improvements in quality of life from first, second and third line treatments. Patients with advanced NSCLC are also benefiting from treatment with novel biological therapies, though their exact role has yet to be completely defined. Furthermore, several trials have now also clearly documented the benefit to patients form adjuvant treatment following resection of early-stage NSCLC.

Non-small Cell Lung Cancer

Systemic chemotherapy has three potential roles in the management of patients with NSCLC: first, as palliative treatment of advanced disease (Stages 111B [with a pleural effusion] and IV [and MI]), second, in complementing radiotherapy for locally advanced disease (Stages IIIAN2 or IIIB [without a pleural effusion] and third, in complementing surgery for early-stage resectable disease (Stages I to IIIA [N1]) – the latter either post-operatively (termed adjuvant chemotherapy) or preoperatively (known as neo-adjuvant chemotherapy).

Type
Chapter
Information
Lung Cancer , pp. 99 - 119
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Non Small Cell Lung Cancer Collaborative Group. (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ, 311, 899–909.CrossRef
Cullen, M. H., Billingham, L. J., Woodroffe, C. M., et al. (1999). Mitomycin, ifosfamide, and cisplatin in unresectable non small cell lung cancer: effects on survival and quality of life, J Clin Oncol, 17, 3188–94.CrossRefGoogle ScholarPubMed
The Elderly Lung Cancer Vinorelbine Italian Study Group. (1999). Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst, 91, 66–72.CrossRef
Ellis, P. A., Smith, I. E., Hardy, J. R., et al. (1995). Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer, Br J Cancer, 71, 366–70.CrossRefGoogle ScholarPubMed
Depierre, A., Chastang, C., Quoix, E., et al. (1994). Vinorelbine versus vinorelbine plus cisplatin in advanced non small cell lung cancer: a randomised trial. Ann Oncol, 5, 37–42.CrossRefGoogle Scholar
Chevalier, T., Brisgand, D., Douillard, J. Y., et al. (1994). Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non small cell lung cancer: results of a European multicentre trial including 612 patients. J Clin Oncol, 12, 360–7.CrossRefGoogle Scholar
Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., et al. (1998). Randomised trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol, 16, 2459–65.CrossRefGoogle Scholar
Cardenal, F., Lopez-Cabrerizo, M. P., Anton, A., et al. (1999). Randomised phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non small cell lung cancer. J Clin Oncol, 17, 12–18.CrossRefGoogle ScholarPubMed
Crino, L., Scagliotti, G. V., Ricci, S., et al. (1999). Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: a randomised phase III study of the Italian Lung Cancer Project. J Clin Oncol, 17, 3522–30.CrossRefGoogle Scholar
Sandler, A. B., Nemunaitis, J., Denham, C., et al. (2000). Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non small cell lung cancer. J Clin Oncol, 18, 122–30.CrossRefGoogle ScholarPubMed
Giaccone, G., Splinter, T. A., Debruyne, C., et al. (1998). Randomised study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non small cell lung cancer. The European Organisation for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol, 16, 2133–41.CrossRefGoogle Scholar
Bonomi, P., Kim, K., Fairclough, D., et al. (2000). Comparison of survival and quality of life in advanced non small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol, 18, 623–31.CrossRefGoogle ScholarPubMed
Schiller, J. H., Harrington, D., Belani, C. P., et al. (2002). Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med, 346, 92–8.CrossRefGoogle ScholarPubMed
The diagnosis and treatment of lung cancer. National Collaborating Centre for Acute Care, Commissioned by National Institute of Clinical Excellence document, February 2005.
Rodriquez, J., Parvel, J., Pluzanska, A., et al. (2001). A multicenter randomized phase III study of docetaxel and carboplatin versus vinorelbine and cisplatin in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology, abstract 314.
Ettinger, D. S. (2002). Is there a preferred combination chemotherapy regimen for metastatic non small cell lung cancer? TheOncologist, 7, 226–33.CrossRefGoogle Scholar
Chevalier, T., Scagliotti, G., Natale, R., et al. (2005). Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer, 47, 69–80.CrossRefGoogle ScholarPubMed
Cornella, P., Frasci, G., Panza, N., et al. (2000). Randomised trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol, 18, 1451–7.Google Scholar
Georgoulias, V., Ardavanis, A., Tsiafaki, X., et al. (2005). Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomised trial, J Clin Oncol, 23, 2937–45.CrossRefGoogle Scholar
Hotta, K., Matsuo, K., Ueoka, H., et al. (2004). Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer, J Clin Oncol, 22, 3852–59.CrossRefGoogle ScholarPubMed
Roszkowski, K., Pluzanska, A., Krzakowski, M., et al. (2000). A multicentre, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer. Lung Cancer, 27, 145–57.CrossRefGoogle ScholarPubMed
Shepherd, F. A., Dancey, J., Ramlau, R., et al. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095–103.CrossRefGoogle ScholarPubMed
Hanna, N., Shepherd, F. A., Fossella, F. V., et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589–97.CrossRefGoogle ScholarPubMed
Mountain, C. (1997). Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710–17.CrossRefGoogle ScholarPubMed
Arriagada, R., Bergman, B., Dunant, A., et al. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med, 350, 351–60.Google ScholarPubMed
Strauss, G. M., Herndon, J., Maddaus, M. A., et al. (2004). Randomised clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer: report of Cancer and Leukaemia Group B (CALGB) protocol 9633. Proceedings of American Society of Clinical Oncology, abstract 621.Google Scholar
Winton, T., Livingston, R., Johnson, D., et al. (2005). Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med, 352, 2589–97.CrossRefGoogle Scholar
Douillard, J., Rosell, R., Delena, M., et al. (2005). ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non-small cell lung cancer patients:final results after 70 month median follow-up. On behalf of Adjuvant Navelbine International Trialist Association. Proceedings of the American Society of Clinical Oncology, abstract 7013.
Scagliotti, G. V., Foassati, R., Torri, V., et al. (2003). Randomised study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst, 95, 1453–61.CrossRefGoogle ScholarPubMed
Keller, S. M., Adak, S., Wagner, H., et al. (2000). A randomized trial of postoperative adjuvant treatment in patients with completely resected stage II or IIIa non-small cell lung cancer. N Engl J Med, 343, 1217–22.CrossRefGoogle ScholarPubMed
Waller, D., Peake, M. D., Stephens, R. J., et al. (2004). Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J cardiothoracic Surg, 26, 173–82.CrossRefGoogle ScholarPubMed
Visbal, A. L., Leighl, N. B., Feld, R., Shepherd, F. A. (2005). Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest, 128, 2933–43.CrossRefGoogle ScholarPubMed
Hotta, K., Matsuo, K., Ueoka, H., et al. (2004). Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol, 22, 3860–7.CrossRefGoogle ScholarPubMed
Comets, E., Ikeda, K., Hoff, P., et al. (2003). Comparison of the pharmacokinetics of S-1, an oral anti-cancer agent in Western and Japanese patients. J Pharmacokinetic and Pharmacodyn, 30, 257–83.CrossRefGoogle Scholar
Depierre, A., Milleron, B., Moro-Sibilot, D., et al. (2002). Preoperative chemotherapy followed by surgery compared with primary surgery in respectable stage I (except T1N0), II and IIIa non-small cell lung cancer. J Clin Oncol, 20, 247–53.Google Scholar
Pisters, K., Vallieres, E., Bunn, P., et al. (2005). S9900: A phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin chemotherapy in early-stage non-small cell lung cancer: preliminary results. Proceedings of the American Society of Clinical Oncology, abstract 7012.CrossRef
Rosell, R., Cobo, M., Isla, D., et al. (2005). ERCC mRNA-based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small cell lung cancer patients. Proceedings of the American Society of Clinical Oncology, abstract 7002.
Fukuoka, M., Yano, S., Giaccone, G., et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol, 21, 2237–46.CrossRefGoogle ScholarPubMed
Kris, M. G., Natale, R. B., Herbst, R. S., et al. (2002). A phase II trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proceedings of the American Society of Clinical Oncology, abstract 292.
Giaccone, G., Herbst, R. S., Manegold, C., et al. (2004). Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial: INTACT 1. J Clin Oncol, 22, 777–84.CrossRefGoogle ScholarPubMed
Herbst, R. S., Prager, D., Hermann, R., et al. (2004). TRIBUTE-a phase III trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. Proceedings of the Amercian Society of Clinical Oncology, abstract 7011.
Gatzemeier, U., Pluzanska, A., Szczesna, A., et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology, abstract 7010.
Shepherd, F. A., Pereira, J., Ciuleanu, T. E., et al. (2004). A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of 1st line or 2nd line chemotherapy, A National Cancer Institute of Canada Clinical Trials Group Trial. Proceedings of the American Society of Oncology, abstract 7022.
Lynch, T. J., Bell, D. W., Sordella, R., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med, 350, 2129–39.CrossRefGoogle ScholarPubMed
Sandler, A. B., Gray, R., Brahmer, J., et al. Randomized phase II/III trial of paclitaxel/carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group study: E4599. Proceedings of the American Society of Oncology, abstract 4.
Fanucchi, M. P., Fossella, F., Fidias, P., et al. (2005). Bortezomib +/− docetaxel in previously treated patients with advanced non-small cell lung cancer: a phase II study. Proceedings of the American Society of Clinical Oncology, abstract 7034.CrossRef
Lynch, T. J., Lilenbaum, R., Bonomi, P., et al. (2004). A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology, abstract 7084.
Johnson, B. E. and Heymach, J. V. (2004). Farnesyl transferase inhibitors for patients with lung cancer. Clinical Cancer Research, 10, 4254s–5457s.CrossRefGoogle ScholarPubMed
Chute, J. P., Chen, T., Feigel, E., et al. (1999). Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol, 17, 1794–1801.CrossRefGoogle ScholarPubMed
Evans, W. K., Osoba, D., Shepherd, F. A., et al. (1985). Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung. J Clin Oncol, 3, 65–71.CrossRefGoogle ScholarPubMed
Einhorn, L. H., Crawford, J., Birch, R., et al. (1988). Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol, 6, 451–6.CrossRefGoogle ScholarPubMed
Sundstrom, S., Bremnes, R. M., Kaasa, S., et al. (2002). Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and Vincristine regimen in small-cell lung cancer: results from a randomised phase III trial with 5 years' follow-up. J Clin Oncol, 20, 4665–72.CrossRefGoogle Scholar
Souhami, R. L., Law, K. (1990). Longevity in small cell lung cancer: A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research, 61, 584–9.PubMed
Lassen, U., Osterlind, K., Hansen, M., et al. (1995). Long-term survival in small-cell lung cancer: post treatment characteristics in patients surviving 5 to 18+ years: an analysis of 1,714 consecutive patients. J Clin Oncol 13, 1215–20.CrossRefGoogle Scholar
Watkin, S. W., Hayhurst, G. K., Green, J. A. (1990). Time trends in the outcome of lung cancer management: A study of 9090 cases diagnosed in the Mersey Region, 1974–86. Br J Cancer, 61, 590–6.CrossRefGoogle ScholarPubMed
Sandler, A. B. (1997). Current management of small cell lung cancer. Semin Oncol, 24, 463–76.Google ScholarPubMed
Kelly, K. (2000). New chemotherapy agents for small cell lung cancer. Chest, 111(Suppl 1), 156S–162S.CrossRefGoogle Scholar
Pawel, J., Schiller, , Shepherd, , et al. (1999). Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer. J Clin Oncol, 17, 658–67.CrossRefGoogle Scholar
Huisman, C., Postmus, P. E., Giaccone, G., Smit, E. F. (1999). Second-line chemotherapy and its evaluation in small-cell lung cancer. Cancer Treat Rev, 25, 199–206.CrossRefGoogle ScholarPubMed
Roth, B. J., Johnson, D. H., Einhorn, L. H., et al. (1992). Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol, 10, 282–91.CrossRefGoogle ScholarPubMed
Fukuoka, M., Furuse, K., Saijo, N., et al. (1991). Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alteration of these regimens in small-cell lung cancer. J Natl Cancer Inst, 83, 855–61.CrossRefGoogle Scholar
Tjan-Heijen, V. C., Postmus, P. E., Ardizzoni, A., et al. (2001). Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol, 12, 1359–68.CrossRefGoogle Scholar
Steward, W. P., Pawel, J., Gatzemeier, U., et al. (1998). Effects of granulocyte-macrophage colony-stimulating factor and dose-intensification of V-ICE chemotherapy in small cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol, 16, 642–50.CrossRefGoogle ScholarPubMed
Murray, N., Livingston, R. B., Shepherd, F. A., et al. (1999). Randomised study of CODE versus alternating CAV/EP for extensive-stage small cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol, 17, 2300–8.CrossRefGoogle Scholar
Furuse, K., Fukuoka, M., Nishiwaki, Y., et al. (1998). Phase III study of intensive weekly chemotherapy with recombinant granulocyte colony-stimulating factor versus standard chemotherapy in extensive disease small-cell lung cancer. J Clin Oncol, 16, 2126–32.CrossRefGoogle ScholarPubMed
Lorigan, P., Woll, P. J., O'Brien, , et al. (2005). randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst, 97, 666–74. Erratum in: J Natl Cancer Inst, 97, 941.CrossRefGoogle ScholarPubMed
Kelly, K., pan, Z., Wood, M. E., et al. (1999). A phase I study of paclitaxel, etoposide and cisplatin in extensive-stage small cell lung cancer. Clin Cancer Res, 5, 3419–24.Google ScholarPubMed
Glisson, B. S., Kurie, J. M., Perez-Soler, R., et al. (1999). Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive samll cell lung cancer. J Clin Oncol, 17, 2309–15.CrossRefGoogle Scholar
Earle, C. C., Stewart, D. J., Cormier, Y., et al. (1998). A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer. Lung Cancer, 22, 235–41.CrossRefGoogle ScholarPubMed
Hesketh, P. J., Crowley, J. J., Burris, H. A. III, et al. (1999). Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group Trial. Cancer J Sci Am, 5, 237–41.Google Scholar
Kirschling, R. J., Grill, J. P., Marks, R. S., et al. (1999). Paclitaxel and G-CSF in previously untreated patients with extensive stage small cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol, 22, 517–22.CrossRefGoogle ScholarPubMed
Kudoh, S., Fujiwara, Y., Takada, H., et al. (1998). Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol, 16, 1068–74.CrossRefGoogle ScholarPubMed
Noda, K., Nishiwaki, Y., Kawahara, M., et al. (2002). Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med, 346, 85–91.CrossRefGoogle ScholarPubMed
Hanna, N. H., Einhorn, L., Sandler, A., et al. (2005). Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive stage (ES) small cell lung cancer (SCLC). J Clin Oncol, 23, 1094 (suppl; abstr 7004).CrossRefGoogle Scholar
Thatcher, N., Qian, W., Clark, et al. (2005). Ifosfamide, Carboplatin and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-life Results of the British Medical Research Council Multicenter Randomised LU21 Trial. J Clin Oncol, 23, 8371–9.CrossRefGoogle Scholar
Wakelee, H., Kelly, K. (2004). Novel approaches for the treatment of small-cell lung cancer. Haematol Oncol Clin North Am, 18, 499–518.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×